(III-2A) 19-year-old patient with Down syndrome, with hypertrophic cardiomyopathy, after correction of congenital heart disease: ASD II, VSD, PDA Prof. Piotr Podolec MD PhD, Monika Smaś-Suska MD, Lidia Tomkiewicz-Pająk MD, Maria Olszowska MD PhD
Background Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disorder and has been estimated to occur in one of every 500 persons in the general population. The mortality due to HCM is estimated at 1% per year and it is the most common reason of sudden death (especially in young athletes). The natural history of HCM can be altered by a number of therapeutic interventions: ICDs for secondary or primary prevention of sudden death in patients with risk factors, …